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SUMMARY
 V»'i
I
Multiple myeloma (MM) is a B cell malignancy characterised by the I
presence of a monoclonal population of teiTuinally differentiated plasma
ÿ
cells in the bone marrow. It generally occurs in older people. Clinical 
manifestations result from monoclonal protein (immunoglobulin)
. .
production and accumulation in the serum and / or the urine, anaemia, lytic 
bone disease, hypercalcaemia, renal insufficiency and immune deficiency.
11-6 is thought to be the major growth factor of MM but the part played by
, X:other cytokines in the pathogenesis of the disease is unclear, hi the use of 
cloned U266 cells we hoped to gain an insight into the cytokines that are
:important in the survival / expansion of the myeloma clone. In this study we 
demonstrate that these myeloma clones express a variety of cytokine mRNA S'Itranscripts, IL -la, IL-lp, IL-6, IL-15 and TGF-p. 3IIL-6, although considered the major proliferative factor, was observed in
V:
one clone only. In contrast TGF-P mRNA transcripts were expressed by
‘3many clones. These clones were capable of suppressing T cell responses.
However if IL-15 and TGF-P mRNA transcripts were co-expressed, the %Isuppression of T cell proliferation was more pronounced.
Due to these findings, it was decided to further investigate the effects of |'ï
IL-6 and IL-15 on myeloma clones. Cell studies examining the effects of
?exogenous IL-6 or IL-15 alone or in combination with dexaraethasone on I;3y:
cell cycle, proliferation, apoptosis and cell signalling were performed. The 
U266 cells were found to be sensitive to the anti-proliferative effect of
(iii) i
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V
dexamethasone, while most of the myeloma clones were resistant. IL-6 and
IL-15 were able to protect the U266 cells from the effects of dexamethasone 
at 50|Lig / ml but not at lOOpg / ml. However we observed a significant 
reduction in proliferation when IL-15 was added in combination with
dexamethasone to clone M3 (expresses mRNA transcripts for IL-15, TGF- :?
p). This clone was resistant to dexamethasone alone. The role of IL-15 is 
complex and seems to behave differently depending on what other cytokines 
are present. Further studies may help elucidate the role of IL-15 in the 
pathogenesis of this disease.
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CHAPTER ONE
INTRODUCTION
Multiple myeloma
Historical perspective
The term ‘multiple myeloma’ (MM) was first coined by von Rustizky in 
1873. His patient, a 47-year old man, was found at autopsy to have eight 
separate soft reddish tumours, which he called ‘multiple myeloma’, in the 
ribs, manubrium, thoracic vertebrae and right humerus. On microscopic 
examination, round vesicle-like cells were observed with a nucleus which 
was close to the plasma membrane. However patients with symptoms of the 
disease had been recognised from the mid 1800’s by physicians such as 
Samuel Solly (1844), who observed his patient, Sarali Newbury, to have 
fractures of right radius and ulna, left tibia and fibula, and both femurs at 
post-mortem. Destruction of the bones was also recorded.
Dahymple, a member of the Microscopical Society, described a ‘red 
gelatiniform’ substance comprising nucleated cells akin to myeloma cells in 
a sample he had been sent fr'om Dr Macintrye’s patient, Mr McBean, who 
had died of ‘atrophy from albuminuria’ in 1846. Both Dalrymple and 
MacIntyre airived at a post-mortem diagnosis of malignant bone disease.
When the urine from such patients was heated it was found to ‘abound in 
animal matter’, and its reactions with acid were reported by Macintyi'e 
(1850), a Harley Street consultant and physician to the Metropolitan 
Convalescent histitution and to the Western General Dispensary. Henry
Bence Jones, a physician with a reputation as a chemical pathologist, was 
also sent urine samples, including a specimen from Macintyre, in which 
Bence Jones confirmed the protein content and emphasized the part this 
played in the diagnosis of the disease, thereby lending his name to the urine 
protein in MM.
Owing to the limited understanding of physiology and pathology of the time 
it was not realised that all these individuals were suffering from the same 
condition with vaiydng presentations. It is only with hindsight that we loiow 
today the patients described in these case reports were suffering from 
Multiple Myeloma (MM).
Epidemiology
MM accounts for 10% of haematological malignancies, 1% of all 
malignancies in Caucasians but is more common in the Afro-American 
population (2% of all cancers) (Riedel & Pottern, 1992). The incidence is 
4.7 per 100,000 in Caucasian men and 3.2 in women, but 10.2 and 6.7 in 
Afro-American men and women, respectively. MM is a disease in which the 
incidence increases with age. The median age of patients at time of 
diagnosis is 65 years.
Aetiology
The genetic factors underlying MM remain unknown. There is a conelation 
with the HLA“Cw5 antigen and the G3m (g5) allotype (Leech et al, 
1983:1985), which is more prevalent in the Afro-American population, and 
MM. Social factors apparently do not account for the racial differences in 
the incidence of the disease. Occupational factors however may play a role. 
Exposure to radiation (Riedel & Pottern, 1992), insecticides, herbicides, and 
other organic solvents, may explain the higher incidence of MM in farmers, 
and workers associated with petroleum products.
Clinical Presentation
MM is a B-cell malignancy characterised by a monoclonal proliferation of 
plasma cells, which accumulate in the bone marrow, and the presence of the 
so-called M-component, a clonal immunoglobulin, in the serum and/or in 
the urine (Boccadoro & Pileri, 1995) which is produced by these cells. The 
most common feature of the disease used to be osteolytic lesions with bone 
pain being the most frequent symptom. However owing to a greater 
awareness of the disease the incidence of back pain has decreased to 37% 
(Riccardi et al, 1991) with 20% of MM patients being asymptomatic. 
Pneumonia and pyelonepluitis are the most fr'equent sequelae of recuirent 
bacterial infections. These infections occur due to the clonal expansion of
one type of non-functioning antibody producing plasma cell, usually IgG or 
IgA with occasional IgM or IgD or mixed cases, leading to the lack of 
production of normal antibodies. The suppression of bone marrow function 
by the increased tumour burden leads to anaemia. Renal insufficiency is also 
observed in many patients, which may be owing to various reasons, 
including hypercalcemia, hyperuricemia, amyloid deposits, and tubular 
damage due to monoclonal light chain secretion.
MM is confinned when the bone marrow shows increased plasma cells 
(>1 0 %), lytic bone lesions are detected by magnetic resonance imaging 
(MRI) (X-rays in the United Kingdom) and M-protein is found in the serum 
or urine. Patients who lack all other criteria for MM but have a monoclonal 
protein in the serum or urine are classified as having monoclonal 
gammopathy of undetermined significance (MGUS). One in four of these 
patients will progress to MM whilst in others the M-protein remains stable 
(Kyle, 1994).
Prognosis
MM has an overall survival rate ranging between one and ten years 
depending on the stage of the disease at diagnosis and treatment history. The 
tumour proliferation rate is assessed by the following factors: the bone 
marrow plasma cell labelling index (LI), serum interleukin- 6  (IL-6 ) level, 
and the serum C-reactive protein (CRP) level. The serum level of 
j6 2 -microglobulin, the percentage of bone marrow plasma cells, the serum
haemoglobin level, and the extent of lytic bone lesions are all linlced to 
tumour burden. Prediction of patient survival is linlced to these clinical 
factors using the so-called Durie and Salmon staging system. (Durie & 
Salmon, 1975) There are three stages to this system (Table: 1). Patients are 
stratified according to biochemical and medical markers such as 
haemoglobin, serum calcium, the M-component level and extent of bone 
lesions. Renal function of the patients is also used. Patients are categorised 
into low, medium or high risk. This system is often used to assign patients 
who need chemotherapy, with improved knowledge of objective markers of 
poor prognosis e.g. monosomy 13, it is likely that therapy will be linked 
increasingly to prognosis rather than simply staging.
Treatment o f  M ultiple Myeloma
Conventional anti-neoplastic chemotherapy
Cunently, the most efficacious drugs in the treatment of MM are the 
alkylating agents (melphalan (r-phenylalanine mustard) and 
cyclophosphamide) and glucocorticoids, hi the 1960’s a combination of 
melphalan and prednisone was introduced. It is the principle treatment for 
MM if no neutropenia or tlirombocytopenia is present. The melphalan and 
prednisone combination has a response rate of 50-60% in MM patients: 3% 
of patients lose the M-component (Alexanian et al, 1977) however in the
Table 1 : Durie and Salmon staging system 
Stage I; Low tumour mass
All of the following must be present:
A. Haemoglobin >10.5 g/dl or Haematocrit >32 %
B. Serum calcium level normal
C. Low serum or urine myeloma protein production rates:
1. peak < 5 g/dl
2. IgA peak < 5 g/dl
3. Bence Jones protein < 4 g/24h
D. No bone lesions or osteoporosis 
Stage II: Intermediate tumour mass
All patients who do not qualify for high or low tumour mass categories are 
considered to have intermediate tumour mass.
Stage III: High tumour mass
One of the following abnormalities must be present:
A. Haemoglobin <8.5 g/dl or haematocrit < 25 %
B. Sermn calcium >12 mg/dl
C. Very high serum or urine myeloma protein production rates:
1. IgG peak > 7 g/dl
2. IgA peak > 5 g/dl
3. Bence Jones protein >12 g/24h
D. >3 lytic bone lesions
majority of patients the M-component decreases or stabilises (reduced in 
60%, stabilises in 30% and increases in 10%).
In the 1970’s further combination therapies were introduced, in the hope 
that additional drugs given together would be considered more effective 
than as monotherapies for example. Other drug combinations have been 
administered, for example using various penmitations of the anti­
metabolites (methotrexate and cytosine arabinoside) with the vinca alkaloids 
(vinblastine, vincristine and vindesine), nitrosoureas and antlrracyclines 
(Adriamycin®), but no improvement in outcome has been convincingly 
proven.
Patients relapsing after melphalan and prednisone are usually treated with 
VAD (vincristine, Adrianiycin®, dexamethasone) chemotherapy (Barlogie et 
al, 1984). VAD or VAD based regimens reduce tumour burden more rapidly 
and are usually used in patients with acute or chi'onic renal failure due to the 
fact that the drug removal is mostly non-renal.
High dose chemotherapy
Patients who do not respond to conventional treatment can benefit from high 
dose chemotherapy. McElwain et al (1983) showed a dose-response 
relationship in MM, In refr'actory patients a high rate of complete response
(CR) was induced by the use of melphalan. However mortality from the 
intensive treatment was high (up to 30%) as the myelosupression was so 
long lasting. Autologous bone marrow or peripheral blood stem cell (PBSC) 
transplantation was shown by Barlogie (1986) to reduce the haematological 
toxicity of the high dose melphalan and most young patients are now 
offered this form of treatment, once the disease has been stabilised 
following initial therapy.
Autologous peripheral blood stem cell transplant
This method of rescue therapy is recommended for patients who are less 
than seventy years old at presentation of the disease. Patients are first treated 
with VAD or similar agents for a few months which reduces the number of 
tumour cells. VAD has the advantage of inducing prompt responses without 
producing long-term damage to man'ow stem cells. The patient’s stem cells 
are mobilised and collected, chemotherapy or total body irradiation (TBI) 
then follows. Finally patients receive their previously collected stem cells 
for bone marrow reconstitution. This procedure is now considered safe with 
less than a 2% death rate due to toxicity. A disadvantage of this treatment is 
that even after intensive chemotherapy / TBI, myeloma cells remain. 
Tumour cells may contaminate the stem cells collected for the transplant, 
although no good evidence exists that this is detrimental to the outcome.
Allogeneic bone marrow transplantation
For younger patients (e.g. those imder fifty years of age), an alternative 
may be offered, using an allogeneic transplant of bone marrow from a 
“tissue type” matched sibling donor or matched mu’elated donors (MUD). 
A high death rate persists because of toxicity / infection but 30% of patients 
who achieve a complete remission continue to be disease free six years post­
transplant (Bensinger et al, 1996). New “reduced intensity” allogeneic 
transplants may extend the scope for this form of treatment in future.
Maintenance therapy
Relapse is not delayed by the use of conventional chemotherapy during 
remission. Therefore other maintenance treatments have been sought. The 
cytokine interferon-alpha (IFN-a:) has been used, and in earlier studies 
sm'vival and remission were shown to be increased (Mandelli et al, 1990). 
Later studies, however, suggested an increased duration of remission but not 
in overall survival. IFN-o: has been used in combination with 
dexamethasone with survival duration of 48 months (Salmon et al, 1994). 
However further studies need to be carried out to confirm the effect was due 
to the combination and not just dexamethasone alone.
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Clinical Trials
Amino-bisphosphonates
Osteolytic bone destmction is a major clinical symptom of this malignancy. 
Although patients respond to chemotherapy, progression of skeletal disease 
may occur (Belch et al, 1991). Randomised trials of first-generation 
bisphosphonates etidronate or clodronate or the second-generation amino- 
bisphosphonates pamidronate have been published (Berenson et al, 1996; 
McCloskey et al 1998). Wliilst early small studies showed a reduction in 
bone pain and healing of lesions (McCloskey et al, 2001), no differences 
were found in larger later studies with etidronate. Clinical trials evaluating 
the anti-myeloma effect of new second-generation amino-bisphosphonates 
(inliibitors of osteoclast activity), such as pamidronate are in progress 
(Terpos et al, 2000). A significant reduction in bone pain, skeletal events 
such as the frequency of fractures and hypercalcaemia that is responsible for 
renal destruction was experienced by patients. Therefore second-generation 
amino-bisphosphonates may represent a new type of treatment for MM.
Thalidomide
Studies have confirmed that a high micro vascular density has a poor 
prognostic outcome in MM (Munshi et al, 1998). This correlation has 
brought about clinical trials with thalidomide as this agent has anti-
11
angiogenic effects. Thalidomide has many different fimctions; it has been 
shown to have anti-proliferative and pro-apoptotic effect on myeloma cells 
(Hideshima et al, 2000). The density of cell surface molecules involved in 
the adhesion cascade has been shown to be altered by the administration of 
thalidomide (Geitz et al, 1996). Myeloma cell adhesion to bone marrow 
stromal cells stimulates the secretion of growth cytokines; the alteration of 
this may contribute to the anti-myeloma effect of thalidomide. The 
secretion, biological activity, or removal of cytokines from the bone marrow 
microenviromnent from where they control the growth and survival of 
myeloma, may be affected by thalidomide (Corral et al, 1999). TNF-a was 
suppressed by improved removal of TNF-a mRNA (Moreira et al, 1993) 
and by increasing the effects of a  1-glycoproteins which have anti-TNF-a 
activity (Turk et al, 1996), both of these events were attributed to 
thalidomide. Thalidomide is also responsible for the down regulation of 
IL-6 receptor mRNA and genes involved in cell metabolism and apoptosis 
(Shaughnessy et al, 2000).
Cytotoxic T-cells proliferate and secrete IFN-y and IL-2 in the presence of 
thalidomide, more importantly it induces the expansion of non-MHC 
restricted natural killer cells that were able to kill autologous myeloma cells 
(Davies et al, 2001).
The exact mechanism that is responsible for the anti-myeloma activity of 
thalidomide remains miknown.
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Biology o f Multiple Myeloma
Monoclonal gammopathy of undetermined significance (MGUS) is a 
common pre-malignant monoclonal expansion of plasma cells which often 
comes before MM. It occurs in 1 % of the adult population and progresses at 
a rate of 1% per year to MM. However after years of research there is no 
known way to identify those who will progress from MGUS to MM, or how 
to prevent this progiession.
However in 50% of MM tumours IgH translocations occur and it has been 
suggested that this is a primary event but that secondary IgH or IgL 
translocations can occur throughout tumour progiession from MGUS to 
intramedullaiy MM to plasma cell leukaemia (PCL) to cell lines (fig 1).
Oncogenesis o f  multiple myeloma
The cytogenetics of MM has been examined in several studies (Dewald et 
al, 1985; Durie B, 1992). The most important clrromosome abnormality in 
MM is a monosomy involving clrromosome 13. This abnormality is 
obseiwed in 50% of patients. Chromosome 13 abnormalities (13q-) are 
associated with an adverse outcome and advanced stages of MM but it is not 
clear if it is a causative lesion.
The 14q32 chiomosomal region was the most recognized abnormality 
(Bergsagel et al, 1996; Nishida et al, 1997). Translocations with different 
chiomosomal partners were shown in 70-75% of patients (Avet-Loiseau et 
al, 1998). The most frequent recuiTent translocations were t (11; 14), with
13
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the upregiilation of the cyclin D l; and t (4; 14) which up regulates the 
receptor 3 for the fibroblast growth factor (FGF). Although these two 
translocations occur in 33% of instances involving 14q32, in other cases the 
partner is unknown. Hyperdiploidy as a second cliromosomal abnormality is 
seen in 50-65% of patients, the chromosomes gained are mainly odd 
numbered (3, 5, 7, 9, 11, 15, 19) and associated with poorer prognosis 
(Barlogie et al, 1983)
hi spite of progi'ess in the understanding of cytogenetic changes, their part in 
oncogenesis of MM remains uncertain.
Oncogenes
MM disease progiession is associated with the p53 tumour suppressor gene 
and the Myc, Bcl-2 and Ras oncogenes. Malignant plasma cells from 
patients with MM ofren over express Myc, and p21 Ras or ectopic ally 
express Bcl-2 oncoproteins. The constitutive c-myc and Ras gene 
expression in MM may be an early event within the transformation process 
or a result of either an imbalanced cytokine network or activation of other 
upstream oncogenes within the signal transduction pathway. At diagnosis 
40% of patients have mutations of N and K-ras increasing to 49% at time of 
relapse (Liu et al, 1996)
Point mutations of the p53 gene have been observed in 4% of 
intramedullaiy MM, and in 25-40% of patients with extramedullary MM or 
acute relapsed MM and in 60% of HMCL (Corradini et al, 1994).
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Immunophenotype o f plasma cells
The CD38 antigen is used to identify plasma cells (Harada et al, 1996). 
Although this marker is widely distributed in the haemopoietic system, 
plasma cells express this antigen at a much higher intensity than other cells 
allowing it to become in effect a specific marker for plasma cells (Leo et al, 
1992). Antibodies PCA-1, PCA-2 (Anderson et al, 1983), 62B1, 8A 
(Tazzari et al, 1987), R I-3 (Gronchoroff et al, 1986) have been produced 
that can identify antigens on plasma cells but they are not specific as they 
also recognise antigens on other haemopioetic cells. Benign and malignant 
plasma cells express syndecan-1 (a heparan sulphate-bearing proteoglycan) 
which was recently recognised by the antibody B-B4 / GDI38 (Wijdenes et 
al, 1996). The GDI38 is not expressed on any of the other cells within the 
haemopoietic compartment. Therefore GD38 and GDI38 are the markers 
used for recognising plasma cells.
Plasma cells show a phenotypically heterogeneous profile. Reactivity was 
shown for GD38, GD9, CD 10, HLA-DR, GD20 and for the myeloid markers 
GDI3 and GD33 (Terstappen et al, 1990). This heterogeneity may represent 
the differentiation from the immature plasmoblast (slg'^, GD10\ GD19\ 
GD20-", HLA-DR-", GD38^^) to the mature plasma cell (slg‘, GDI O', GDI 9', 
GD20', HLA-DR', GD38"^) (Tominaga et al, 1989).
Phenotypic characteristics of myeloma plasma cells varied from normal 
plasma cells on their expression pattern of GD19 and GD56 (Rawstron et al,
1997). Bone marrow myeloma cells expressed the phenotype GDI9' GD56^
16
whereas noimal plasma cells from different tissues expressed the phenotype 
CD 19  ^ CD56" (Harada et al, 1993). Recently, weak CD56 expression was 
observed on a minor subpopulation of normal plasma cells (Ocqueteau et al, 
1998). CD56 is an adhesion molecule, an isoform of N-CAM which was 
involved in homophillic and heterophillic interactions.
It was also obseiwed that, although the normal plasma cells had the 
phenotype CD 19^, there was a small population that remain negative for this 
marker. Therefore the phenotype that best distinguishes the malignant 
plasma cells usually is lack of expression of CD 19 but strong expression of 
CD56^^.
Adhesion molecules
Some molecules are required for adliesion to the intercellular and bone 
maiTow matrix, namely CD44 (H-CAM), CD49, CD56, galactosyl residues, 
rhamm (hyaluron), syndecan-1, and fibronectin. Others are required for 
intercellular communication, such as C D lla, CD54 (I-CAM-1), and CD58 
(LFA-3).
Normal plasma cells have been shown to express VLA-4 (CD49d/CD29), 
VLA5 (CD49e/CD29), (3-2 integrins, CD44 and I-CAM-1 (Leo et al, 1992, 
Harada et al, 1993, Barker et al, 1992, Van Ri et I, Van Camp B. 1993). 
N-CAM expression has been shown to be low (Pellat Deceunynck et al, 
1994,1995) or not found (Barker et al, 1992, Leo et al, 1992). On noimal 
plasma cells LFA-3 was not expressed (Barker et al, 1992) while LFA-1
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was undetectable (Aslunann et al, 1992, Barker et al 1992) or expressed at 
low levels (Pellat-Deceunynck et al 1995).
Myeloma cells express syndecan-1 (Wijdenes et al, 1996, Livingston et al, 
1996), CD44 (Hamilton et al, 1991, Picker et al, 1988, Uchiyama et al, 
1992) and CD54 (Hamilton et al 1991, Harada et al, 1993). CD44 and CD54 
remain up regulated during the acute phase of MM and were expressed in 
extramedullary proliferation and on hmnan myeloma cell lines. Whereas 
CD56 (N-CAM) which was strongly expressed on MM cells (Van Camp et 
al, 1990, Van Riet et al, 1991, Barker et al, 1992) was down regulated 
during the acute phase of the disease as well as LFA-1 (Ashmann et al, 
1992). MM cells also expressed LFA-3 (Barker et al, 1992). Reduced cell­
cell interaction may encourage dissemination of the disease. Loss of 
adhesion molecules may allow cells to escape immune detection.
Bone marrow microenvironment
The clonal tumour cells have plasma cell morphology, and are present in, 
and spread tluough, the haematopoietic bone maiTOw. Extramedullary 
disease is present in advanced cases, with many myeloma plasma cells 
accumulated in the peripheral circulation. It is acknowledged that the bone 
maiTow microenvironment may contribute to tumour cell survival and 
proliferation (Meredith et al, 1993). Cytokines and growth factors existing 
in the mieroenviromuent may control cell growth, survival and migiation of 
the tumour cell (fig 2). Myeloma cells can produce factors such as IL-1/5, 
Tumour necrosis factor (TNFce) and lymphotoxin which promotes the
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Figure 2 : Representation o f the possible interaction between 
myeloma cells and bone. M yeloma cells produce factors that are able to 
promote bone re-absorption.The environment generated by resorbing bone, 
including the products released by the bone, osteoclasts and osteoblasts can 
promote the proliferation and survival o f myeloma cells
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synthesis of IL-6 by isolated osteoclasts (Garrett et al, 1995; Giovanni et al, 
1996). Bone marrow stromal cells secrete IL-6 which is a paracrine growth 
factor for myeloma. Activation of the JAK2 / STATS by IL-6, results in the 
over expression of Bcl-X*  ^ and inhibition of CD95 induced apoptosis 
(Cartlett-Falcone et al, 1999). Tumour survival can also be controlled by 
cell-cell or cell-ECM (extracellular matrix) adhesion (Clark & Brugge,
1995). CD95 induced apoptosis was blocked by myeloma cell adhesion to 
fibronectin (Shain et al, 2002). Therefore these host-tumour cell interactions 
may provide the means by which the myeloma clone can survive and 
proliferate.
Cytokines and growth factors
hiterleukin-6 (IL-6) is a pleiotropic cytokine that was originally identified as 
B-cell stimulatory factor 2 (BSF-2) (Kishimotol989). Owing to its 
multifunctional roles IL-6 was also formerly described as interferon-P2 
(IFN-pz), hybridoma / plasmacytoma growth factor (HPGF), and 
hepatocyte-stimulating factor (HSF). IL-6 is produced by many cell types, 
including T cells, B cells, bone marrow stromal cells, endothelial cells 
monocytes and tumour cells. Myelomas and plasma cell leukaemias express 
EL-6 mRNA (Freeman et al, 1989). Light and electron microscopy were 
used to detect cytoplasmic IL-6 in myeloma cells of the bone marrow 
(Ohtake et al, 1990). Patients with advanced MM were given neutralising 
anti-EL-6 murine monoclonal antibodies (Klein et al, 1991), which in some 
cases reduced the suiwival and proliferation of malignant plasma cells,
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suggesting that this cytokine has a central role in the pathogenesis of MM.
I■'g
IL-6 supports survival of MM plasma cells by the prevention of
■Iprogrammed cell death (Lichtenstein et al, 1995) and / or inducing tumour f
expansion and resistance to dexamethasone (Hardin et al, 1994).
This cytokine was originally described as an autocrine growth factor for 
myeloma cells (Kawano et al, 1988; Bar ut et al, 1992), but evidence now 
exists supporting the theoiy of a paracrine secretion of IL-6 from the tumour 
enviromnent of the bone marrow (Klein et al, 1989; Klein 1995). Bone 
maiTow stromal cells, osteoblasts and osteoclasts secrete IL-6 (Caligaris- 
Cappio et al, 1992) that in turn is thought to be controlled by IL-ip that was 
released by the tumour cells (Klein 1995).
, r |
The IL-6 receptor (IL-6R) has two subunits: the a  chain (gp80 or EL-6Ra)
and the p chain (gpl30 or IL-6Rp). Receptor activation necessitates the
binding of IL-6 to the IL-6Ra followed by phosphoiylation of the IL-6RP
(transducer chain). IL-6 is part of the family of six cytokines that use the
gpl30 as the transducer chain: oncostatin M (OSM), leukaemia inhibitory
factor (LIF), IL-11, ciliary neurotropic factor (CNTF) and cardoiphin 1.
Some MM cell lines react to LIF, OSM or CNTF when an appropriate
receptor is expressed (Zhang et al, 1994). The soluble form of the IL-6Ra
was found to amplify the sensitivity of myeloma cell lines to IL-6 and may
.therefore lead to expansion of myeloma cells (Gaillard et al, 1993). While a #
Îpoor prognosis is envisaged if high levels of IL-6 are found in the serum no 
such coiTelation has been found with soluble IL-6R.
1  
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Interleukin-10 (IL-10) is a pleiotropic cytokine expressed by many cell 
types including monocytes, B cells and macrophages. This cytokine inliibits 
pro-inflammatoiy cytokines (Hulin et al, 1996) and enliances the 
proliferation of human B-cell precursors and mature B cells activated by 
anti-IgM mAbs, Staphylococcus aureus Cowan (SAC)(Rousset et al, 1992). 
IL-10 is a growth factor for malignant plasmablastic cell lines, and IL-10 
dependent MM cell lines have been developed (Lu et al, 1995). MM 
patients have raised levels of ILIO in their serum which correlates with the 
M-protein level (Ameglio et al, 1995).
Vascular endothelial growth factor (VEGF) has been detected in MM cells. 
This cytokine stimulates cells of the microenvironment to secrete IL-6 
which is a major growth factor for MM (Danbar et al, 1998).
Interleukin-15 (IL-15), a cytokine which was recently discovered was found 
to share activities of IL-2. It was initially identified for its ability to induce 
T-cell proliferation. Proliferation of normal B cells has also been induced by 
IL-15 (Aiiiiitage et al, 1995). It is a member of the four-helix bundle 
cytokine family. IL-15 interacts with a heterotrimeric receptor that consists 
of the beta and gamma subunits of the IL-2 receptor as well as a specific, 
high-affmity IL-15 alpha subunit (IL-15Rœ). The IL-15Ro! is required for 
high-affinity binding but not signalling by IL-15 (Anderson et al, 1995b). 
Many tissues and cell types produce mRNA for IL-15 (Jonuleit et al, 1997; 
Blauvelt et al, 1996). Bone maiTOW stromal cell lines, primaiy human bone 
marrow stromal cells (Mrozek et al, 1996) and fetal intestinal epithelium
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(Mmi'ay et al, 1998) also produce IL-15 which indicates a role in 
haematopoiesis. IL-15 may play a part in chronic inflammatory and 
autoimmune diseases as it operates as a potent chemoattractant for T-cells 
(Wilkinson & Liew, 1995). EL-15 is a proinflamatory type one cytokine 
(Klian & Kasper, 1996; Seder, 1996) although it has sometimes been 
observed as a type two cytokine stimulator (Mori et al, 1996; Ruckert et al,
1998). Abnormal IL-15 or IL-15R expression has been linked with 
lymphoid malignancies (Mezza et al, 1998; Trentin et al, 1996). MM cells 
expressed the IL-15 alpha receptor (IL-15Ra) and this cytokine may be 
implicated in the autocrine propagation of this disease (Tinliofer et al, 
2000).
Transforming gi'owth factor-beta (TGF-p) was first identified by its ability 
to induce reversibly the phenotypic transformation of fibroblast cell lines 
(Roberts et al, 1981). TGF-p is a pleiotropic cytokine that affects many 
cells, both normal and transfoitned. hi culture TGF-p induces cell 
proliferation of fibroblasts (Leof et al, 1986), osteoblasts (Centrella et al, 
1987) and smooth muscle cells (Battegay et al, 1990). However in many 
cells TGF-p inhibits proliferation, in that cell cycle arrest can occur in 
epithelial cells if  TGF-p is added during early G1 (Laiho et al, 1990). TGF- 
P also has an immumnodulatory role; it inliibits cell proliferation of T 
lyiuphocytes, B lymphocytes, thymocytes, large gi'anular lyiuphocytes, 
natural killer cells, and lymphocyte-activated killer cells (Kelirl et al, 1986a; 
Ristow, 1986; Rook et al, 1986; Kuppner et al, 1988; Wahl et al, 1988a; 
Ortaldo et al, 1991). The immumnodulatory response depends on the
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differentiation state of the cell and cytokine exposure. Many cytokines are 
inliibited by TGF-p, the effects and or the production of interferon-y, tumour 
necrosis factor-a, tumour' necrosis factor-p, interleukin-1, interleukin-2, 
interleukin-3 and the expression of the interleukin-2 receptor (Espevik et al, 
1987,1988; Ohta et al, 1987; Ranges et al, 1987; Letterio and Roberts,
1998). The important effector functions in the TGF-p induced 
immunosuppression is the effect of cell cycle aii'est and the inhibition of 
cytokine production. However TGF-p can also enhance immature 
lymphocyte proliferation (Cei-wenka et al, 1994) and inhibit T-lymphocytes 
apoptosis (Cei-wenka et al, 1996; Rich et al 1996). B-cell differentiation and 
iiumunoglobulin expression is also controlled by TGF-p. Studies of TGF-p 
have shown it to act as both tumour suppressor (Arteaga et al, 1990; Glide et 
al, 1993,1994; Pierce et al, 1995; Cui et al, 1996) and promoter (Sieweke et 
al, 1990; Welch et al, 1990; Steiner and Barrack, 1992; Arteaga et al, 1993). 
hr multiple myeloma studies have shown the presence of TGF-p mRNA in 
tumour cells and cell lines (Mathes et al, 1993; Klein, 1995; Cook et al,
1999). Multiple myeloma cells secrete higher levels of TGF-p than normal 
B cells; also patients with MM produce higher levels of TGF-p in bone 
marrow than controls (Urashima et al, 1996). High serum levels of TGF-P 
have also been obseiwed in patients with MM and may relate to the extent of 
myeloma bone disease (Kroning et al, 1997). The part played by TGF-p in 
the pathogenesis is not clear, it may be involved in the survival of these 
myeloma cells or it may be involved in TGF-P mediated immune 
suppression (Cook et al, 1999; Campbell et al, 2001).
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Characteristics o f the U266 Human myeloma cell line (HMCL)
The myeloma cell line U266 is an extremely well characterised line 
described initially by Nilsson et al in 1970. Although unusual in being an 
IgE A cell line, it expresses the major myeloma plasma cell characterising 
antigens on a high percentage of the cells. Thus, PCA-1 and CD44 (H- 
CAM) aie 90-100% positive. CD38 and CD 138 (Syndecan-1) are present 
on 50-90% of the cells, while B cell lineage markers such as CD 10, CD 19, 
and CD20 are present in less than 10%. However, the fact that not all U266 
cells are positive for CD38 / CD138 suggests a degree of heterogeneity 
within the cell population, and it was for this reason that the development of 
sub-clones of the line might produce some variation in characteristics 
between individual clones.
AIMS
The growth of multiple myeloma plasma cells may depend on complex 
interactions between the tumour cells, an assortment of cytokines and the 
bone / bone microenvironment. Although IL-6 is an essential paracrine / 
autocrine growth factor in MM, the part played by other cytokines in the 
pathogenesis of MM is not clear.
hi addition to its phenotypic characteristics, U266 grows readily in tissue 
culture, and it was therefore identified as a robust, available, and appropriate 
model for myeloma plasma cells in these experiments.
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Recent work in our laboratory has explored the relationship between TGF-P 
produced by MM cells and the suppression of anti-plasma cell T cell 
responses. There anergic T cells can have their responses reinstated by 
exposure to IL-15, following which they are once again able to respond to, 
and enter the autocrine cycle of, IL-2. Clinical studies are plamied that will 
explore the effect of IL-15 at restoring T cell anti-myeloma activity in vivo, 
by stimulating T cells with CD3 and IL-15 ex vivo before re-infusing them 
to patients. Therefore it was important to explore the effect of IL-15 and 
IL-6 against myeloma plasma cells. In addition, the potent anti myeloma 
agent Dexamethasone was included in the experiments to observe the 
possible impact of a therapeutic agent on the cytokine effects.
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CHAPTER TWO
METHODS
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METHODS
Tissue Culture Techniques
Maintenance and Growth o f Cell Lines
U266 human myeloma cell lines were grown in suspension in RPMI 1640 
medium with 10% foetal calf serum and 1% glutamine (RPMT), in a 
humidified incubator at 37 °C in an atmosphere of 5% (v/v) CO2 , Every 3-4 
days cells were counted using a haemocytometer and set up at 1 x 1 0  ^ cells 
per flask (1 x 10  ^cells /ml) with fresh RPMU.
Storage and recovery o f frozen cells
Cells were washed by centrifugation for 5 minutes at lOOg in a MSE 
Centaur 2 centrifuge. The pelleted cells were resuspended in 90% PCS / 
10% DMSG at a concentration of 5x10^-1x10^ cells / ml and aliquoted into 
1ml Nunc cryotubes. The cryotubes were allowed to freeze slowly overnight 
in polystyrene (about l°C/min) to -70°C after which they were tiansferred 
to liquid nitrogen. Nunc cryotubes were thawed by placing in a waterbath at 
37°C, the cells were transferred to a universal container, h'esh RPMI^ was 
added and cells washed as described to remove DMSO. The cells were then
2 8
Testing fo r Mycoplasma
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resuspended in RPML and seeded in a 25cm^ tissue culture flask, and 
incubated at 37°C, 5% CO2
The adherent fibroblast cell line NRK.49, was seeded in 60mm dishes at 
0.25 xlO"* cells / ml in 4ml of fresh RPMfr. In addition, conditioned media
(2 ml) which had been in contact with the cells for a minimum of 2  days was 
added to the dishes. One dish of NRK49 cells was set up in parallel with 
fresh RPMfr as a control. The NRK49 cells were then incubated for 3-4
. 3:
days at 37°C. The medium was removed and the cells washed twice with
.2.5ml of PBS and then 2.5ml of fixative (3 volumes methanol SS: 1 volume 3
Iglacial acetic acid) was slowly added to each dish. Cells were then washed
I
twice more with 5ml of fixative for 10 minutes each wash. The dishes were i
3:inverted and left to drain. To each dish, 5ml of PBS containing 0.05ug / ml 
Hoechst 33258 stain was added and left for 10 minutes at room temperature. -
The stain was discarded and the dishes washed twice with distilled water.
The fixed cells were examined for mycoplasma using a fluorescence 
microscope with a water immersion lens. Hoescht 33258 is a stain for DNA; 
negative cells have only the nuclei stained whereas positive cells have 
staining within the cytoplasm, thus confmuing contamination with 
mycoplasma.
RNA ISOLATION
RNeasy^
Approximately 1x10^ cells were lysed in RLT-mercaptoethanol buffer 
(350|al). The lysate was loaded onto a QIAshredder®. The column was then 
spun sitting on a 2ml collection tube for 2 minutes at 21,250g, and the 
homogenized lysate collected. An equal volume of 70% ethanol was added 
(350pl) and mixed well by pipetting. This sample was then applied to an 
RNeasy® mini spin column sitting on a 2ml collection tube which was spun 
for 15 seconds at 10,840g. The flow-through was discarded. RWl buffer 
(700pl) was pipetted onto the RNeasy® column which was centrifuged at 
10,840g for 15 seconds. The RNeasy® column was transferred onto a new 
2ml collection tube, ethanol re-constituted RPE buffer (500pl) was pipetted 
onto the column and this was centrifuged at 10,840g for 15 seconds, and 
again the flow-through was discarded. RPE buffer (500pl) was again 
pipetted onto the column and centrifuged at 21,250g for 2 minutes to dry the 
RNeasy® membrane. The RNeasy® column was transferred to a new 1.5ml 
collection tube, RNase free water was added (30ju,l) onto the column and the 
assembly was then centrifuged at 10,840g for 1 minute. The optical density 
of the eluted RNA was measured at 260nm. The quantity of RNA was 
calculated as follows. RNA (5pi) was diluted with distilled water (495pi) 
and absorbance (A260) was measured in a 1ml cuvette using a BioQuest
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spectrophotometer (Cecil CE2501). An absorbance (A260) of 1 was 
equivalent to 40pg / ml of RNA, the concentration (in pg per ml) of RNA in 
each sample was calculated by absorbance (A260) x 40 x dilution factor. 
Therefore the total amount of RNA in each sample equaled the product of 
concentration multiplied by the original volume of the sample (ml).
Trizol®
Approximately 10  ^ cells were lysed in 1ml of Trizol® for 5 minutes at room 
temperature, which permits the complete dissociation of nucleoprotein 
complexes. Chloroform was added (0.2ml chloroform per 1ml of Trizol) 
then the sample tubes were capped securely, shaken vigorously by hand for 
15 seconds and then incubated at room temperature for 2-3 minutes. 
Samples were then centrifuged at 12,000g for 15 minutes at 4°C. 
Centrifugation separated the mixture into a lower pink chloroform phase, a 
protein interphase, and a colourless aqueous phase. The RNA remained in 
the aqueous phase which was transferred to a fresh tube and precipitated by 
the addition of 0.5ml of isopropyl alcohol per 1ml of Trizol reagent. The 
samples were incubated at room temperature for 10 minutes followed by 
centrifugation at 12,000g for 10 minutes at 4°C. The supernatant was 
discarded and the pellet washed once with 1ml of 75% ethanol. The samples 
were mixed by vortexing and centrifuged at 7,500g for 5 minutes at 4°C. 
The RNA pellets were then air dried and resuspended in RNase free water. 
Incubation for 10 minutes at 55°C assisted RNA dissolution.
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RT-PCR
cDNA Synthesis
Oligo (dT) 12-18 primer (0.5qg of primer per 5pg of RNA) was hybridized 
to the poly (A) tail of mRNA to be used as a primer for first strand cDNA 
synthesis with reverse transcriptase. This mixture (22 pi of RNA solution + 
2pl of primer) was heated to 70°C for 10 minutes, and then quickly chilled 
on ice. The tube was centrifiiged at 10,840g for 10 seconds. The following 
mixture was added to the tube: 8pi 5x First-Strand Buffer, 4pl O.IM DTT, 
2pl dNTP (lOmM each dATP, dGTP, dCTP, and dTTP), 2pl Reverse 
Transcriptase (Superscript™ II). The tube was then equilibrated at 20°C for 
5 minutes. The temperature was then raised to 42°C, which was the optimal 
temperature for the enzyme activity for 50 minutes then raised to 95°C for 5 
minutes to inactivate the enzyme. The cDNA produced was then amplified 
in a polymerase chain reaction.
Polymerase Chain Reaction
This method was used to amplify cytokine and receptor sequences, 2pi of 
cDNA was mixed with 48pl of PCR mix (containing 20mM Tris-HCl, 
50mM KCl; 2.5mM MgCfr; 0.2mM of each of dATP, dCTP, dTTP, and 
dGTP; 0.25pM of the cytokine primer pairs (Table: 2); 0.4 units Taq 
polymerase). PCR amplification was carried out using a Hybaid 
programmable thenuocycler. The samples were denatured at 95 °C for 3
3 2
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minutes, then 30 cycles of 95°C for 1 minute, 65°C for 1 minute, 72°C for 1
■Ïminute, followed by a final 5 minute extension at 72°C. The products of
■I:PCR samples were run on 2% agarose gels containing 10 pg / ml ethidium
1;
bromide with molecular weight markers to determine the size of the |
products. A reaction was considered positive if  a band of the appropriate 
size was visible and negative control lanes remained clear (including a no 
RT control).
Primers
Most primers used in these studies were published sequences (Kotake et al,
1996). Primers were selected which would result in a cDNA product which 
spanned introns to ensure that the product was not the result of DNA
contamination.
Î'
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Table: 2 Oligonucleotide PCR primer sequences
CYTOKINE FRAGMENT 
SIZE (bp)
SEQUENCE
P-Actin-5'
p-Actin-3'
548 GTGGGGCGCCCCAGGCACCA
CTCCTTAATGTCACGCACGCACGATTTC
IL-la-5'
IL-la-3'
421 GTCTCTGAATCAGAAATCCTTCTATC
CATGTCAAATTTCACTGCTTCATCC
IL-lp-5'
IL-ip-3’
802 ATGGCAGAAGTACCTAAGCTCGC
ACACAAATTGCATGGTGAAGTCAGTT
IL-2-5'
IL-2-3'
266 ACTCACCAGGATGCTCACAT
AGATAATCCATCTGTTCAGA
IL-4-5'
IL-4-3'
456 ATGGGTCTCACCTCCCAACTGCT
CGAACACTTTGAATATTTCTCTCTCAT
IL-6-5’
IL-6-3'
628 ATGAACTCCTTCTCCACAAGCGC
GAAGAGCCCTCAGGCTGGACTG
IL-10-5'
IL-10-3'
352 TCTCAAGGGGCTGGGTCATATCCCA
ATGCCCCAAGCTGAGAACCAAGACCCA
IFN-7-5'
IFN-y-3'
495 ATGAAATATACAAGTTATATCTTGGCTTT
GATGCTCTTCGACCTCGAAACAGCAT
TNE-œ-S’
TNF-a-3'
695 ATGAGCACTGAAAGCATGATCCGG
GCAATGATCCCAAAGTAGACCTGCCC
TGF-/3-5'
TGF-i3~3'
181 ACCATGATCGTGCGCTCTGCAAGTGCAGC
AAGGAATAGTGCAGACAGGCAGGA
IL-15-5' 
IL-15-3'
393 TGGAAACCCCTTGCATAGCCAGCTCTT
CTGTATCATGAATACTTGCATCTCCGGACTC
IL-15R-5'
IL-15R-3’
538
439
GCGGGGATCCACGTGCCCTCCCCCCAT
GTCCGTGGAA
CCACAAGCTTGTCGCTGTGGCCCTGTG
GATACACAC
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CELL STUDIES
Cell Proliferation
Cell proliferation was measmed by the amount of ^H-labelled thymidine 
incorporated into the replicating DNA of cultured cells. Cells were set up in 
25cm^ flask at 1x10^ cells / ml in RPMC. The cytokine (IL-15) or 
glucocorticoid to be assessed was added, they were then aliquoted (200pl) 
per well in RPMI^ onto a microtitre plate (96 well) and cells incubated at 
37°C in a humidified incubator for 3 days. Then 0.5pCi of ^H-labelled 
thymidine was added to each well, after 24 hours the plates were haiwested 
onto filter paper by automatic cell harvester. The incorporation of 
labelled thymidine was measured by counting in a Packard Matrix beta- 
counter.
Cell Cloning
U266 cells were seeded at 0.2x10^ cells / ml in 25mm^ dishes containing 
RPMC / 0.9% Methocult. The plates were incubated at 37°C in a humidified 
incubator and observed for the formation of colonies. The colonies were 
then removed from the semi-solid medium, numbered and separately grown 
in fresh RPMC. This step was repeated and these cells were known as 
cloned myeloma cells (Brown et al, 1995).
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Annexin V Affinity Assay
The externalisation of phosphatidylserine (PS) is one of the earliest events 
of programmed cell death (Martin et al, 1995). Annexin V was used to 
detect PS externalisation (Engeland et al, 1998). PS occurs early in cell 
death and remains until cell necrosis. Annexin V was used with a vital dye 
propidium iodide (PI) therfore identifying three populations of cells: live 
cells (AnVPT), early apoptotic cells (An^/PT) and late apoptotic/necrotic 
cells (An^/PI^). The Annexin V-affinity assay was used for the detection of 
apoptosis. Cells were washed with PBS for 5 minutes (x2) at 140g using a 
MSE Centaur 2 centrifuge. Annexin V, (Catalogue Number 65874X fi'om 
BD Biosciences) (5 pi) and 5 pi of lOOpg / ml propidium iodide were added 
and incubated in the dark at room temperature for 15 minutes. They were 
resuspended in Ix Annexin V Binding Buffer (10^ cells / ml; R & D 
Systems). Cells were analysed within an hour of the incubation. Controls 
were set up as follows, cells were resuspended in Binding Buffer only, cells 
resuspended in Annexin V alone, cells in propidium iodide alone, analysis 
was carried out using Cell Quest software (Becton Dickinson).
Cell cycle assays
The cell cycle stage of cell nuclei was determined, using the stain 
propridium iodide (PI). The amount of PI absorbed is directly proportional 
to the amount of DNA in the nucleus. PI staining was carried out using the
3 6
Mixed Lymphocyte Reactions (MLR)/Mitogen stimulation o f f  cells
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DNAConS kit (Dako) according to the manufacturer’s instructions. Briefly,
DNAConS tubes were re-constituted with the supplied PI solution to 
provide a cell lysis and staining solution. (This contains cell lysis buffer to 
give a free suspension of nuclei; RNAse to stop non-specific binding of PI 
to RNA; and a chromatin stabilizer to help make staining more uniform).
Approximately 10  ^ cells per sample were incubated in re-constituted
■tDNAConS solution for one hour with vigorous vortexing (x4 during this Iperiod of time). Samples were then directly analysed on a FACScan using 
Cell Quest software (Becton Dickinson). Nuclei were gated to exclude I
debris and analysed on a linear FL-2 scale (fig.3). PI staining generated 
characteristic cell cycle histograms depicting cell nuclei in Go/Gi, S phase 
and G2/M phases of the cell cycle. Cell cycle analysis was carried out using 
Wincycle for Windows Software (Coulter Immunotech). This programme 
combines 6 different algorithms to estimate cell cycle status of the sample -  
a sample result is contained in figure: 3
A proliferative response is generally observed when lymphocytes of 2 
individuals of different HLA types are co-cultured. This results from the 
reaction of T cells of an individual to major histocompatibility (MHC) 
antigens on the other individual’s cells which were measured by tritiated 
thymidine uptake. It has been observed that U266 cells were extremely poor 
at inducing MLR reactions, as soluble factors produced by the U266 cells
Figure :3  Histogram o f  cell cycle
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Representative DNA histogram U266 or myeloma clones 
stimulated with IL6, IL-15 analysed by modfit software. 
The cells within the first peak represent cells in phase 
of cell cycle, with the cells to the right o f this peak 
representing cells that have progressed to S phase and G2/M
phase o f cell cycle.
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suppresses the T cell proliferation induced (Cook et al 1999). Also, soluble 
factors from HMCL suppress the proliferation of T cells induced by the 
mitogen Concanavalin A (Con A)(Cook et al, 1999). To test whether clones 
which expressed differing cytokine mRNA species generated during this 
project had differing effects on T cell activation, clones were assessed for 
their ability to provoke MLR responses and to suppress Con A-induced 
proliferation.
Peripheral blood mononucleai" cells (PBMNC) were separated from the 
peripheral blood of normal, healthy volunteers by centrifugation over ficoll- 
hypaque, followed by 4 washes in PBS. PBMNC were re-suspended in 
RPMC at 4x10^ cells / ml for MLR and 8x10^ cells / ml for Con A assays. 
Stimulator MM clones were treated with 50pg / ml Mitomycin C (Sigma) 
for 30 minutes at 37^C followed by 3 washes in RPML. For MLR 
reactions, lOOql / well of responder PBMNC were seeded in wells of a 96 
well plate. lOOpl of stimulator MM clones were then added to the wells to 
give concentrations of responder: stimulators of 1:5-1:160. For Con A 
stimulation, wells were set up with 50pl of responder: stimulators of 1:5- 
1:160. For Con A stimulation, wells were set up with 50pl of PBMNC in an 
identical mamier to the MLR plus lOOpl of Con A at 5pg / ml (Final Con A 
concentration = 2.5fig / ml). Proliferation was assessed by the uptake of 
0.5pCi of tritiated thymidine to the cultures during the last 18hours of 
culture. Cells were harvested onto frbreglass membranes and counted using 
a Packard Matrix counter. Con A-induced proliferation was assessed at 3
3 9
days, MLR reactions were assessed at 5 days, although Con A Conti'ol wells 
were added to MLR plates and assessed at 5 days.
TGF-jgl ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
The detection of active TGF-jSl in supernatants of U266 HMCLs was 
analysed using a Promega ELISA kit. U266 cell suspensions were 
centrifuged at lOOg for 5 minutes, washed in PBS (x3) and resuspended at a 
concentration of Ix 10  ^cells / ml in fresh RPMT. RPMI^ alone was set up 
as a control. The U266 cells were cultured in a humidified incubator at 37°C 
in an atmosphere of 5% (v/v) CO2 for 3 days. The cell suspensions and 
controls were centrifuged at lOOg for 5 minutes and supernatants were 
removed, acidified for 15 minutes at room temperature, then neutralized as 
this assay was designed to measure biologically active TGF-jSl. All
. Psamples were diluted with sample buffer to obtain readings within the range |
of the ELISA kit (16-lOOOpg / ml). These samples were analysed following 
the manufacturer’s instructions. The results were expressed minus control 
samples.
STATISTICAL ANALYSIS
..-ft'
All statistical analysis of experimental data was carried out with Microsoft 
Excel analysis software (Microsoft Office 2000). Where data represents 
more than 3 observations, this was presented as the mean +/- standard 
deviation of the mean. Two-sample student t-test was used for comparison
4 0  i
of data groups. The statistical significance of difference between two data 
groups was expressed as the probability or p  value. Statistical significance 
was indicated if the p<0.05, with the gi'eater significance being indicated to 
the lesserp  value.
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CHAPTER THREE
RESULTS
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Cytokine profiling of myeloma clones
Positive control RNA was prepared from peripheral blood mononuclear 
cells (PBMNC) cultured in the presence of PH A/PM A for 4-6 hours. The 
cells were harvested, mRNA was isolated using RNEasy® or Trizol, and 
cDNA prepared as described in Materials and Methods. Optimisation of 
the PCR reaction was initially achieved by titration of the magnesium 
chloride (MgClg) concentration in a specific PCR for actin using the 
positive control cDNA (Fig 4). From this titration, 2.5 mM MgCh 
concentration was then used in all subsequent PCR reactions. All primer 
sets were tested in specific PCR reactions with positive conti'ol cDNA.
The cell line U266 (which was mycoplasma negative) was cloned as 
previously described. The mRNA from the clones was studied using RT- 
PCR. Twenty-three clones (M1-M23) were isolated. Ten clones were 
examined. These ten were chosen because they exhibited the most 
vigorous growth within the clones isolated. The clones were examined 
for the expression of the following cytokines (Table 3): interleukin-la 
(R -la ) , IL-ip, IL-2, IL-4, IL-6, IE-10, interferon gamma (IFNy), tumour 
necrosis factor-alpha (TNF-a), transfoiming growth factor-beta (TGF-P), 
IL-15 and IL-15 alpha receptor (IL-15Rq!). The clones were found to 
exhibit different cytokine profiles. M5 produced mRNA for IL -la, IL- 
ip , IL-2, and TGF-P (fig 5), whilst the M6 clone did not (fig 6), this 
clone was only positive for actin. M8 clones were positive for cytokines
4 3
IL-1 a , IL-4, and TGF-p. M l clones were positive for cytokines IL-6 and 
TGF-P (Fig 7). All clones constantly transcribed TGF-p mRNA with the 
exception of M6 which, after remaining negative for TGF-p for six 
weeks, became positive for TGF-p mRNA (fig 8). All the clones that 
were examined transcribed mRNA for IL-15ce receptor (fig 9). All clones 
were regularly examined and with the exception of M6 retained their 
cytokine profile throughout these experiments.
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Figure 4 : Optimisation o f  M gCl2 Concentration
548bps
A c t i n T G F - p
-181 bps
M H 2 O 0.5 1 1.5 2 2.5 3 1 1.5 2 3
Magnesium Chloride (mM)
Figure 4 : Optimization of PCR reaction was achieved by titration 
of magnesium chloride in a specific PCR for actin using positive 
cDNA. A 2.5mM concentration of magnesium chloride was 
used in all subsequent PCR reactions
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Figure 5 : Cytokine profiling by PCR o f  Clone M5
lOOObps
500bps
1000bps 
500bps
181bps
Actin IL la  IL4 y  IFNy CD80
IL lp  IL2 IL6 TGF- lCAM-1 CD86
P
Figure 5 : Clone M5 expressed mRNA transcripts for 
Actin, IL-la, ILl-6, IL-2 and TGF-13
Figure 6 : Cytokine profiling by PCR o f  clone M6
548bps
1000bps 
500bps
t t t t t t Bi  ft  t t
A ctin IL ltx IL4 ■  ' IFNy C'DSO
I L l p  1L2 IL ( ) H 'G F - P  ICAM -1 C D 86
Figure 6: Clone M6 expressed mRNA transcripts for Actin
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Figure 7 : cytokine expression o f  IL-6 in clone M l
M l
628bps
Figure 7 : Clone Ml expressed mRNA transcripts for IL-6
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Figure : 8 Myeloma clone M6 after six 
weeks
1000bps 
500bps 548bps
181bps
Markers TGF-P ACTIN
Figure 8 : Clone M 6 after six weeks now 
produced mRNA transcripts o f TGF-P
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Figure 9 : Expression o f  IL -15a receptor 
by PCR o f  m yelom a clones
538bps
439bps
Figure 9 : Ail clones expressed 
mRNA transcripts of IL-15 ce receptor 
2 bands the smaller product is a splice 
variant lacking exon 3
1 - M l  4 - M 6  
2 - M 3  5 - M 7
3 - M 5  6 - MS
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Effects of myeloma clones on Immunosuppression
Clones M5 and M6 displayed different patterns of cytokine inRNA
and MLR reactions as previously described. M5 at a ratio of 1:80 (MM: 
PBMNC) showed moderate suppression of ConA induced proliferation (fig 
10). The higher the concentration of M5 cells the lower the level of induced 
proliferation in the MLR (fig 11). In contrast, clone M6 did not suppress 
ConA induced proliferation (fig 10), but permitted a normal MLR reaction 
(increased levels of stimulators increased the level of proliferation) (fig 11). 
Therefore clone M6 which did not express TGF-p by PCR neither
cytokines as expressed by clone M5 (IL-la, IL-lp, IL-2). M3 expressed 
mRNA for IL-15 and TGF-P, whilst M9 expressed mRNA for TGF-p.
51
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expression (fig 5 and fig 6 respectively). M6 was the only clone that did not
■IIexpress TGF-p. These clones were tested for their ability to suppress ConA
f
suppressed ConA nor MLR induced proliferation in T cells, whereas the
TGF-p producing M5 suppressed ConA and at high concentration of 
stimulator reduced proliferation.
s
Clones M3 and M9 (fig 12) did not express any of the T cell stimulating
I:
When M3 was tested for it’s ability to suppress Con A and MLR reactions, 
M3 suppressed Con A proliferation but failed to induce an MLR response 
(figs 13, 14). However M9 suppressed (51%) Con A proliferation at a ratio 
of 1:5 (fig 14). Therefore a MM clone (M3), which expressed mRNA for 
IL-15 and TGF-p was an efficient T cell inhibitor whereas a clone (M9) 
which did not co-express mRNA for IL-15 and TGF-P was a poor T cell 
inliibitor.
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Figure 10: Effects of Clone M5, M6 on Con A 
induced proliferation
"G 160%2 140% 
c  1 2 0 %<S 100% 80% 60% _ 40% ® 20% ^ 0%
Q)
■ M6 
□ M5
Figure 10: Clone M5 which expressed TGF-P shows moderate 
suppression of Con A induced proliferation whereas no 
suppression was seen with Clone M6 which did not express 
TGF-p
KEY PBMC = peripheral blood mononuclear cells: Con A 
lM(myeloma clones):5PB = ratio of clones;peripheral blood 
mononuclear cells
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Figure 11: Clone MS, M6, MLR response with PBMNC 
from a normal donor
Q.
ü
4000
3500
3000
2500
2000
1500
1000
500
0
N'
■ M5 
0  M6
N'
Figure 11 : Clone M6 demonstrates a modest MLR response to PBMC from a 
normal donor after 5 days whereas with clone M5 the higher concentration of 
myeloma cells the lower the level of induced proliferation in the MLR.
Key 1M;5PB -  the ratio myeloma cells :PBMC
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Figure 12 : C ytokine profile o f  clones M3
a n d M 9
545bps
392bps
181bps
545bps
181bps
Figure 12 : RT-PCR for the expression o f Actin, TGF-P and IL-15 
mRNA transcripts from the two clones M3, M9. M3 expressed 
mRNA transcripts for Actin, TGF-P and IL-15. M9 expressed 
mRNA transcripts for Actin and TGF-P
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Figure 13 : C lone M3 response to M LR  
with PBM C s from a normal donor
1MM:5PBMC 1MM:10PBMC 1MM:20PBMC
Figure 13 : Clone M3 which expressed mRNA transcripts 
for IL-15 and TGF-/3 failed to induce an MLR response at 
the highest concentration of myeloma clones.
Key ; 1MM:5PBMC
Ratio of myeloma clones to PBMCs
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Figure 14 : Effects o f  M3 and M9 on Con A  
induced proliferation
70%
: 30%
f  20%
10% -
0%
1MM:5PBMC 1MM;10PBMC 1MM;20PBMC
Figure 14 : Clone M3 suppressed ConA proliferation 95% 
at a concentration of 1 myeloma cell : 5 peripheral blood mononuclear 
cells whereas clone M9 at the same concentration suppressed ConA
proliferation 50%
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Effects of exogenously added IL-6 or IL-15 alone or in 
combination with dexamethasone, on proliferation, cell cycle 
progression and apoptosis
The effects o f  exogenously added IL-15 on proliferation.
The U266 cells were set up as previously described in “Materials & 
Methods”. Various concentrations of the cytokine IL-15 (O.Olng / ml-lOng / 
ml) were assessed for an ability to increase U266 proliferation, a significant 
difference was noted with O.lng / ml and lOng / ml (fig 15), lOng / ml of 
IL-15 was used in the following experiments as this was the concentration 
used in the T cell experiments (Campbell et al, 2001).
Effects o f  exogenously added IL-6 or IL-15 alone or in combination with 
dexamethasone, on proliferation.
U266
The cell line U266 was dexamethasone sensitive, that is dexamethasone 
decreased proliferation of the cells (figs 16, 17). IL-15 alone did 
significantly decrease proliferation (fig 16, p = l.OlE-05). IL-6 alone did
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increase proliferation (fig 16, NS). IL-6 and IL-15 protected against 
sensitivity to 50 fig / ml dexamethasone (fig 16) but not at 100 fig / ml 
dexamethasone (fig 17).
Myeloma clone M l
This clone was resistant to dexamethasone, that is dexamethasone did not 
decrease proliferation of the M l clone (fig 18). IL-6 did not increase 
proliferation (fig 18) whilst IL-15 did significantly increase (p < 0.005) 
proliferation. The effect of IL-15 in combination with dexamethasone was 
to increase proliferation (fig 18). IL-6 in combination with dexamethasone 
potentiated proliferation of this clone (fig 18) but was not statistically 
significant.
Myeloma clone M3
This clone was resistant to dexamethasone, that is no decrease in 
proliferation was seen (fig 19). IL-15 slightly increased proliferation (fig 
19). IL-6 reduced proliferation (fig 19, NS). IL-15 in combination with 
dexamethasone significantly decreased proliferation (fig 19, p = 0.033). 
as which IL-6 in combination with dexamethasone (fig 19, p=0.0011).
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Myeloma clone M l 6
This clone was resistant to dexamethasone at 50pg / ml but not at lOOpg / 
ml (fig 21, p=0.011). IL-15 in combination with dexamethasone did not 
affect resistance to dexamethasone (figs 20, 21). IL-6 in combination with 
dexamethasone had no effect on dexamethasone resistance (fig 21).
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Figure 15 : Effects o f  exogenously added IL-15 on U 266
proliferation in vitro
180%
160% -
140% -
2 120%
0  1 0 0 %
1  80%
® 60% 4 0 .
40% -
20% -
0.01 0.1 1 
IL-15 (ng/m L)
10
Figure 15 : The proliferation of U266 myeloma cells were 
significantly increased by the addition of IL-15 at 
concentrations of O.lng / ml (p = 0.015) and lOng /ml (p =0.026) 
with respect to the control Ong /ml of IL-15.
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Figure 16: Effects o f  IL-6 / IL-15 in combination 
with 50|Lig / ml o f  Dexamethasone on U 266  
proliferation in vitro
z0Ü
zUi
Ëlij0.
140% 1—
120% ■—
100% • 1
80% ■
60% • T
40% ■
20% • 1
0%-
CONTROL DEX IL-6 IL-8+DEX IL-15 IL-15+DEX
Figure 16 : U266 cells were sensitive to dexamethasone 
(50pg / ml) that is dexamethasone significantly decreased 
proliferation (p = 6.5E-11). IL-15 alone significantly 
decreased proliferation (p = 0.001). IL-6 and IL-15 
protected against dexamethasone (p = 0.001) sensitivity
62
Figure 17 : Effect o f  exogenously added IL-15 
in combination with Dexamethasone on U 266  
proliferation in vitro
120%-!
100%-
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Figure 17 : The cell line U266 was sensitive to dexamethasone alone 
(p<0.005) or in the presence of various concentrations of IL-15 
Dexamethasone (lOOpg / ml) decreased proliferation significantly 
(p<0.005) with respect to the control.
DEX = lOOpg / ml
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Fig 18 : Effect on in vitro  proliferation o f the clone 
M l in response to exogenously added IL-6, 
Dexamethasone, IL-15, or
IL-6 / IL -15 in combination with Dexamethasone 
180% " ----
140% -
ô  1 20% -I
o 100%-1
40% -
20%  ■
g 80% 4 
oQ.
Control DEX IL-6 IL-6 + IL-15 IL-15+
DEX DEX
Figure 18 : Clone Ml was resistant to dexamethasone, that is 
dexamethasone (50pg / ml) did not decrease proliferation. 11-6 
did not increase proliferation, whilst IL-15 did significantly 
increase proliferation (p<0.005) with respect to the control.
DEX =50pg / ml
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Figure 19 : Effect on in vitro  proliferation o f  
the clone M3 in response to exogenously  
added IL-6, Dexamethasone, IL-15, or IL-6 / 
IL -15 in combination with Dexamethasone
160% T
140%_i
g  120%- 
z  100% 4
O 80%
UJ 60% 4 
m 40%Q.
20%
o%4
IL-6+DEX
15+DEX
CONTROL
Figure 19 : Clone M3 is resistant to dexamethasone. that is no decrease 
in proliferation . IL-6 in combination with dexamethasone significantly 
decreased proliferation (p = 0.001). IL-15 in combination with 
dexamethasone significantly decreased proliferation (p = 0.033 ).
DEX=50pg /ml
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Figure 20 : Effect o f  exogenously added 
Dexamethasone and IL -15 alone, or in 
combination, on in vitro  proliferation o f  the 
M l6 clone
120% 1
100% ■
80% ■
60% -
*
40% -
20% -
Control DEX 1L15 IL-15 + DEX
Figure 20 ; Clone M l6 was sensitive to dexamethasone 
(lOOpg / ml), that is proliferation was significantly 
decreased (p =0.001). Exogenous IL-15 significantly 
increased proliferation (p= 0.0068) but did not protect 
against the effects of dexamethasone. 
p values calculated with respect to control
DEX = 1 OOpg / ml
66
Figure 21 : Effect on in vitro  proliferation o f  the 
clone M l6 in response to exogenously added 
IL-6, Dexamethasone, IL-15, or IL-6 / IL-15 in 
combination with Dexamethasone
140% -,
120% •
100 /o ■
O 80% ■
z  60%
S 40%'
20%  '
CONTROL IL-6+ DEX IL-15 IL-15+DEX
Figure 21 : Clone M l6 was resistant to dexamethasone 
( 50pg / ml), that is no decrease in proliferation. Exogenous 
IL-6, IL-15 alone or in combination with dexamethasone 
had no significant effect on proliferation of this clone
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TABLE : 4 Profile of myeloma clones examined in cell
studies
ACTIN IL-6 IL-15 TGF-p
U266 + - - +
M l + + - +
M3 + - + +
M16 + - - +
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Cell Cycle
Effects o f  exogenously added IL-6 or IL-15 alone or in combination with 
dexamethasone, on cell cycle and apoptosis
U266
When exogenous IL-6 alone was added to the U266 cells, the proportion of 
cells in Gi (-15%) stage decreased while cells in S (+15%) and Gi (+12%) 
stage increased (table: 5) thus supporting the proliferation results, with a 
slight decrease in apoptosis (increase of -4% on control). No change in the 
proportion of cells in Gi (+2%), S phase and G2 (0%) was shown with 
exogenous IL-15 alone (Table: 5). Exogenous IL-6 in combination with 
dexamethasone reduced the amount of cells in Gi significantly (p = 0.007) 
and increased the cells in S phase (p = 0.007) that was indicative of 
proliferation (table: 5). Exogenous IL-15 in combination with
dexamethasone (lOOpg / ml or 200pg / ml) showed a slight reduction in Gi 
and an increase in S phase (Table: 5).
Clone M l
The clone was dexamethasone resistant. The cell cycle stages of the clone 
were not significantly altered with the various concentrations of 
dexamethasone (Table: 6). Exogenous IL-6 alone did not change Gi phase 
nor S phase (-3%) of the cell cycle of the M l clone (Table: 6). When 
exogenous IL-15 was added alone, it decreased the proportion of cells in G2 
(-60%) phases. Dexamethasone in combination with IL-6 variably altered
6 9
the proportion of cells in S phase and only reduced the proportion of cells in 
Gz phase (-20%) at the dexamethasone concentration of lOOpg / ml. IL-15 in 
combination with dexamethasone more than doubled the proportion of cells 
in Gz phase (from 60% to 140%), but decreased the proportion of cells in S 
phase (-22%) and depending on the concentration of dexamethasone used 
increased (+9%) or reduced (-8%) the proportion of cells in Gi, No 
significant differences were observed possibly due to insufficient data, 
rather than that there were no significant differences.
Clone M2
This clone was resistant to dexamethasone. Wlien this clone was treated 
with lOOpg / ml dexamethasone alone (table: 7). There were minor changes 
in the proportion of cells in Gi (reduced from 73% to 68%) and in the 
proportion of cells in S phase (increased from 24% to 32%). A slight 
increase was observed in the proportion of cells in Gz stage (+33%) of the 
cell cycle with the addition of IL-6 (NS). The addition of IL-15 did not 
change the proportion of cells in Gi (-4%) or S phase (+12%). EL-6 in 
combination with dexamethasone had no significant effect on the proportion 
of cells in cell cycle. At the lOOpg / ml dexamethasone concentration the 
proportion of cells in Gi was not altered (-6%) while the propoifion of cells 
in Gi at the 200pg / ml dexamethasone was slightly decreased (-14%). The 
combination of EL-15 and dexamethasone (lOOpg /ml or 200pg / ml) 
reduced the proportion of cells in G% and slightly increased the proportion of 
cells in S phase (+12%).
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Clone M l 6
The clone was resistant to dexamethasone. The various concentrations of 
dexamethasone (Table: 8) increased the proportion of cells in S phase. After 
the addition of IL-6 to the clone, the proportion of cells in S phase (+20%) 
increased with no change in Gi but a reduction in Gz phase (-31%). The 
addition of IL-15 alone to the clone induced no change in Gi (+3%) but 
increased the proportion of cells in S phase (+65%) with a decrease in Gz 
phase (-94%) cells (Table: 8). The addition of IL-6 in combination with 
dexamethasone, increased the proportion of cells in S phase at 50pg / ml 
and lOOpg / ml dexamethasone (+6%, +55% respectively) with a reduction 
in Gz (50%-100%). The combination of IL-15 with dexamethasone 50pg / 
ml showed no change the proportion of cells in Gi (+2%) or S phase (-6%) 
with an increase in Gz (+50%).
Apoptosis
Apoptosis of the clones was not increased by the use o f dexamethasone. 
When dexamethasone was used in combination with IL-6 or IL-15 apoptosis 
was variable.
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Table: 5 Effects of exogenous IL-6 or IL-15 alone or in combination
with dexamethasone on U266 cells
* Dex 50 == Dexamethasone 50pg / ml
+ Percentage cells in (percentage change with respect to control)
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Gi S G2/M Apoptosis
DexO 52 33 16 24
IL-6 44(-15%) 38(+15%) 18(+12%) 23(-4%)
IL-15 53(+2%) 33(0%) 15(-6%) 27(+12%)
Dex 50* 59 28 14 29
IL-6 44(-25%) 39 (+39%) I8(+28%) 26 (-10%)
IL-15 46(-22%) 38 (+36%) 15(+7%) 14 (-52%)
Dex 100 61 24 16 23
IL-6 44(-28%) 37 (+54%) 19 (+19%) 20 (-13%)
IL-15 57(-7%) 30 (+25%) 14 (-13%) 23 (0%)
Dex 200 62 25 14 24
IL-6 43(-30%) 38 (+52%) 20 (+43%) 40 (+65%)
IL-15 57(-8%) 29 (+16%) 8 (-43%) 29 (+21%)
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Table 6: Effects of exogenous IL-6 or IL-15 alone or in combination
with dexamethasone on cell cycle of the clone M l
Gi S Gz/M Apoptosis
Dex 0 62 34 5 18
IL-6 62 (0) 33 (-3%) 6 (+20%) 16 (-11%)
IL-15 62 (0) 32 (-6%) 2 (-60%) 19 (+6%)
Dex 50 62 38 5 16
IL-6 63 (+2%) 33 (-13%) 5(0) 17 (+6%)
IL-15 59 (-5%) 32 (-16%) 10 (+100%) 18 (+13%)
Dex 100 63 32 5 18
IL-6 63 (0) 33 (+3%) 4 (-20%) 17 (-6%)
IL-15 58 (-8%) 31 (-3%) 12 (+140%) 23 (+28%)
Dex 200 60 36 5 22
IL-6 63 (+5%) 33 (-8%) 5(0) 15 (-32%)
IL-15 65(+8%) 28 (-22%) 8 (+60%) 25 (+14%)
Dex 50 = 50jig /m l
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Table 7: Effects of IL-6 or IL-15 alone or in combination with
dexamethasone on the cell cycle of the clone M3
G| S Gz/M Apoptosis
Dex 0 73 24 3 24
IL-6 73 (0) 23 (-4%) 4 (+33%) 6 (-75%)
IL-15 70 (-4%) 27 (+12%) 3(0) 3 (-87%)
Dex 50 73 24 3 27
IL-6 73 (0) 23 (-4%) 4 (+33%) 8 (-70%)
IL-15 75 (+3%) 23 (-4%) 3(0) 8 (-70%)
Dex 100 68 32 0 12
IL-6 64 (-6%) 36 (+13%) 0 9 (-25%)
IL-15 66 (-3%) 33 (+3%) 2 5 (-58%)
Dex 200 63 26 11 9
IL-6 73 (+16%) 23 (-12%) 4 (-64%) 15 (+67%)
IL-15 61(-3%) 29 (+12%) 10 (-9%) 5 (-44%)
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Table 8: Effects of dexamethasone in combination with IL-6 or IL-15 
on the cell cycle of the clone M l 6
Gi S Gz/M Apoptosis
DexO 64 20 16 15
IL-6 65 (+2%) 24 (+20%) 11 (-31%) 19 (-27%)
IL-15 66 (+3%) 33 (+65%) 1 (-94%) 13 (-13%)
Dex 50 61 34 4 10
IL-6 62 (+2%) 36 (+6%) 2 (-50%) 15 (+50%)
IL-15 62 (+2%) 32 (-6%) 6 (+50%) 24 (+140%)
Dex 100 62 27 11 12
IL-6 58 (-6%) 42 (+55%) 0 14 (+17%)
IL-15 67 (+8%) 32 (+19%) 0 8 (-33%)
Dex 200 65 35 0 9
IL-6 65 (0) 35 (0) 0 8 (-11%)
IL-15 67(+3%) 31 (-11%) 2 7 (-22%)
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TGF-jS ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
U266 cells were examined for cytokine mRNA transcripts by RT-PCR. 
Cytokine mRNA transcripts for TGF-/31 were observed. The supernatants 
from the U266 cells after 3 days culture were examined for the production 
of TGF-/31 protein by ELISA. This cell line produced significant quantities 
of TGF-|31 when compared to the control which was RPML. U266 cells 
secreted 11+lng / ml of TGF-/31, RPML had a background content of 
4±lng / ml of TGF-j31 (p<0.05).
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CHAPTER FOUR
DISCUSSION
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DISCUSSION
Cytokine profiling of Myeloma clones
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1
IMultiple myeloma is a monoclonal proliferation of plasma cells, although 
the characteristics of the cell of origin have yet to be identified. It has been 
suggested that small terminal deoxynucleotidyl transferase negative CD 10+ 
lymphoid cells of the bone marrow or post-genninal centre may be 
implicated. There have been many attempts to identify the factors that are 
responsible for the giowth and survival of myeloma cells. Although 
myeloma cells produce some of these factors, others are produced and 
secreted by cells of the local microenviromnent. Factors secreted by 
myeloma cells include IL~1(3, IL-6, TGF-p, TNF-p granulocyte colony-
stimulating factor (G-CSF), and macrophage colony-stimulating factor (M- 
CSF)(Soutar et al, 1996). Human myeloma cell lines may be of some
assistance in identifying cytokines which are significant in the progression 
of the disease, particularly those cytokines which are important in 
immunosuppression and tumour expansion.
Although HMCL may be useful in the study of the biology of MM, doubt 
exists as to their usefulness in dissecting events that occur within the bone 
marrow microenvironment as these HMCLs were created from patients with 
advanced disease, which is extramedullary. These HMCLs have an altered 
phenotype and biology compared with malignant plasma cells harvested 
from bone mairow of patients (San Miguel et al, 1995) and may be 
unrepresentative of myeloma cells in the early stages of disease. The down
I
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regulation of the surface antigen CD56 (NCAM) and VLA-5 is linlced with 
extramedullary dissemination. Wliile HMCLs are not exactly representative 
of primary myeloma cells, they share basic characteristics such as Ig gene 
re-arrangement and production of cytokines that make them a useful tool in 
the development of methods to study myeloma cells.
This project involved the cloning of the U266 cell line to obtain different 
phenotypes in order to further examine the role of cytokines in suppression / 
proliferation / development of myeloma.
hi this study we investigated the cytokine profiles of several myeloma 
clones from the IL- 6  independent cell line U266. This cell line, which was 
thought to be monoclonal in origin (Nilsson et al, 1970), produced clones 
that exhibited different cytokine profiles. These clones expressed mRNA 
transcripts for a range of T-cell activating and modulating cytokines. The 
U266 clone M5 expressed mRNA for the T cell stimulating cytokines 
IL -la , IL-lp and E.-2 (fig 5). M 8  clones were positive for the cytokines 
IL -la, IL-4 and TGF-p. M l expressed mRNA for IL- 6  and TGF-p(fig 7). 
M3 expressed transcripts for IL-15 and TGF-P (fig 1 2 ). All clones, with 
the exception of clone M 6 , constantly transcribed TGF-p. These results 
demonstrate heterogeneity within the U266 myeloma clone population as 
regards to cytokine production (figs5-7) and hopefully provide a way of 
examining the effects of individual cytokines on myeloma cells.
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Controversy exists as to the production of IL- 6  and dependency of the U266 
myeloma cell line on exogenous IL- 6  (Barut et al, 1992; Schwab et al, 1991; 
Diamant et al, 1996). In this study IL- 6  mRNA transcripts were detected in 
one clone only whereas the others remained negative (fig7). These 
discrepancies between this and other studies may be accounted for by 
changes in the cytokine profiles with time in culture or in the use of 
different methods of detection that may involve differences in sensitivity.
EL-ip is not produced by normal plasma cells but is found in the majority of 
MM patients (Donovan et al, 1998). IL-1 is believed to be important in the 
pathogenesis of MM (Torcia et al, 1996). Torcia demonstrated that 
osteoclast activating factor (OAF) activity of culture supernatants from 
unfractionated bone marrow cells of MM patients correlated with the IL-lp 
content. Also the use of the IL-1 receptor antagonist, sIL-lR type I or II, 
and neutralizing anti-IL-lp antibodies eliminated OAF activity. These 
results indicate that OAF activity of myeloma cells in humans is related to 
IL-1 p. Interestingly IL-lp increases the expression of adhesion molecules 
and induces paracrine IL- 6  production. These adhesion molecules may be 
responsible for myeloma cells remaining in the bone mairow where the 
production of IL-1 p and the paracrine production of IL- 6  ultimately lead to 
osteolytic lesions. Adhesion molecules may also support the growth and 
survival of myeloma cells within this microenvironment, hi these 
experiments only one clone co-expressed IL -la  and IL-lp(frg 5) and 
another expressed IL-la. It is possible that these differences in expression
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may depend on the different stages of maturation. The U266 myeloma cells 
are extramedullary and therefore at a stage of development where down 
regulation of adhesion molecules might be expected and therefore little or 
no expression of IL-1 mRNA would be anticipated.
IL-15 is a cytokine that shares similar biological activities with 
IL-2 (Grabstein et al, 1994). Proliferation of cytotoxic T cells (Grabstein et 
al, 1994) and survival of NK cells was stimulated by IL-15 (Carson et al, 
1997). Further studies have revealed a proliferation and differentiation 
promoting function of IL-15 in preactivated human B cells (Annitage et al, 
1995). The constitutive expression of IL-15n receptor (IL-15Rn) in 
myeloma cell lines and in plasma cells of MM patients has been observed 
(Hjoith-Hansen et al, 1999). Fmthennore EL-15 transcripts in myeloma cell 
lines have been detected (Tinhofer et al, 2000). These findings may confirm 
the existence of an autocrine EL-15 loop as a method of tumour expansion in 
MM. EL-15 therefore could play an important role in the clonal expansion 
and survival of malignant cells in MM. ha this study IL-15 transcripts of 
mRNA were expressed in one clone only (fig 12). However, all clones 
expressed the IL-15Rn (fig 9). The presence of two amplification products 
538bp and 439bp shown figure 9 is consistent with the existence of two 
alternatively spliced mRNA isofonns characterized by the presence or 
absence of exon 3 (+99bp). IL-15 receptor contains the /3 and 7  chain of the 
IL-2 receptor and a specific a  chain (Giri et al, 1995). The IL-15Rcü is a high 
affinity binding receptor that transduces signals only in the presence of the
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IL-2 / IL-15RjS and 7  chain. Due to the high affinity of IL-15Rq: for IL-15 it 
has been suggested that IL-15 Rn may act as a molecular sink for excess 
IL-15 or may associate receptors yet to be identified (Anderson et al, 1995; 
Kemiedy et al, 1996). In this context the IL-15 receptor found on myeloma 
cells may enlrance the suppression of T cells by capturing IL-15. Blocking 
IL-15 activity inhibits the expansion of memory CDS"^  T cells which play an 
important role in the long term protection against pathogens and tumours.
MM cells secrete TGF-(3 which has suppressive effects on B, T, NK cells 
and macrophages. TGF-p also up regulates IL- 6  secretion from stromal cells 
(Urishima et al, 1996). Autocrine 11-6 can be induced tlirough the activation 
of CD40 with CD40 ligand (CD40L) in MM (Urashima et al 1995). Thus 
TGF-P may be helpful to maintain the malignant clone directly in addition 
to its immunosuppressive effects. Apart from M6  all clones expressed 
mRNA transcripts for TGF-p. However, after six weeks, in culture M 6  also 
expressed mRNA transcripts for TGF-p(fig 8 ).
Effects of Myeloma clones on Immunosuppression
Immune surveillance may fail owing to suppression of immune 
responses by MM cells. Many factors have been implicated in this 
suppression, for example Fas ligand, sMUC-1 and TGF-P, as mediators of T 
cell suppression (reviewed Cook G, Campbell J. 1999). T lymphocytes are 
strongly regulated by TGF-p. T cells that are activated secrete TGF-p and
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exogenous TGF-(3 inhibits IL-2 dependent proliferation (Kerhl et al, 1986a), 
Effector fimctions of activated cells are suppressed by TGF-P’s inhibitory 
effects on the secretion of an assortment of cytokines. Therefore TGF-p 
inhibits the effects and / or the production of interferon-% TNF-o; TNF-/?, 
LL-1, lL-2, IL-3 and the expression the IL-2 receptor (Espevik et al, 
1987,1988; Ohata et al, 1987; Ranges et al, 1987; Letterio &Roberts, 1998). 
A regulatory role in the differentiation of T cells may be performed by 
TGF-P as TGF-p can induce the expression of CD8 . Although the later 
stages of differentiation is inhibited by TGF-P and therefore inlhbits the 
generation of CD4 CD8  cells (Suda & Zlotnik, 1992; Takahama et al, 1994; 
Mossalayi et al 1995). While the generation of Thi cells, a subset of helper 
T cells with a characteristic cytokine secretion pattern was originally 
obseiwed to be promoted by TGF-p (Swain et al 1991), it has now been 
implicated as regulator of Th2 differentiation of cells and a inhibitor of 
T h i  differentiation of cells (Schmitt et al, 1994; Strober et al, 1997).
Tumour cells of MM patients directly inliibit the autocrine IL-2 growth 
pathway in T cells. TGF-P secreted by the tumour was responsible for the 
lack of T cell response (Cook, et al, 1999). hi this study we have obseiwed 
that clones M3 and M5, which expressed transcripts for niRNA of TGF-p, 
suppressed the MLR at high concentration (IMM: 5PBMNC), with 
suppression diminishing as the MM cells were diluted with PBMNCs. This 
was in contrast to M 6  which had not expressed mRNA for TGF-p nor 
suppressed the MLR. In the Con A induced proliferation experiments,
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clones M3, M5 and M9 all suppressed proliferation unlike clone M6  that 
neither expressed niRNA for TGF-P nor suppressed Con A induced 
proliferation. Interestingly the degree of suppression was much stronger in 
the clone M3 that also co-expressed IL-15. In this context this may indicate 
that IL-15 enhances the TGF-p suppression of T cells. Clones therefore that 
co-expressed these two cytokines were better T cell inliibitors.
Cell studies 
Cell proliferation
Although IL- 6  is thought to be a major growth factor in multiple myeloma 
(Klein, et al, 1995) other cytokines may contribute to the expansion of these 
malignant cells. Many cells and tissues constitutively express IL-15 mRNA 
but it is not usually expressed in T, B or Natui'al killer (NK) cells (Bamford 
et al, 1996; Doherty et al, 1996), although it maybe expressed by neoplastic 
T cells (Yamada et al, 1998; Dobbeling et al, 1998). Myeloma cell lines 
express the a  receptor for IL-15, which may play a role in the proliferation 
and or survival of these cells (Tinliofer et al, 2000). This study examined 
the effects of exogenously added IL- 6  or IL-15 alone or in combination with 
dexamethasone on proliferation of U266 cells and myeloma clones.
The effects of exogenously added IL-15 on 0266 proliferation
Proliferation of U266 cells were significantly increased by the addition of 
IL-15 at concentrations of Ing / ml (p<0.05) and lOng / ml (p<0.05) with
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respect to control Ong / ml of IL-15 (fig 15). This data may suggest a role 
for IL-15 in the proliferation of the neoplastic plasma cell.
The effects of exogenously added IL-6 or IL-15 alone or in combination 
with dexamethasone on proliferation
IL-6 did increase proliferation in the U266 cells (fig 16) although not 
significantly. Exogenous IL-6 promotes cell proliferation by 
phosphorylation of the retinoblastoma protein (pRB). When pRB is 
dephosphorylated it binds E2F which prevents cells from leaving G1 thus 
preventing cell growth (Urashima et al, 1997). However IL-6 did protect 
against the effects of dexamethasone. Recent studies have demonstrated that 
IL-6 is an anti-apoptotic factor for myeloma cells. It prevents spontaneous, 
drug induced, and Fas induced apoptosis (Lichtenstein et al, 1995, Hardin et 
al, 1994, Chauhan et al, 1997). Interestingly a significant decrease (p = 
0.001) was observed in proliferation of these U266 cells when IL-15 was 
added. IL-15 also protected the cells from the anti proliferative effects of 
dexamethasone at 50pg / ml (fig 16), but not at lOOpg / ml (fig 17). These 
results may be of some significance as multiple myeloma clinical trials are 
planned, which will investigate the use of IL-15 ex vivo to protect T cells 
from the immunosuppressive effects of myeloma plasma cells. The removal 
of all IL-15 from reinfused cells would be of major importance as IL-15 
may act as a survival / growth factor for myeloma cells (Hjorth-Haiisen et
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al, 1999; Meazza et al, 1998), as well as having toxic effects for the 
recipient.
The myeloma clone M l, which produces transcripts of IL-6 mRNA, was 
resistant to the effects of dexamethasone but a significant increase 
(p=0.0056) in proliferation was obseiwed with the addition of IL-15 (flgl8). 
The clone M3 (expressed IL-15 mRNA) was also resistant to 
dexamethasone but both IL-15 and IL-6 in combination with dexamethasone 
potentiates a significant reduction (p^O.OOl, p=0.03, respectively) in 
proliferation (figl9). M16 was resistant to dexamethasone at 50pg / ml (fig 
21), but not at 100|ag / ml (fig 20) Interestingly IL-15 increases 
proliferation. These different responses may be due to the different cytokine 
profiles exhibited, cell surface receptors, or other soluble factors. The fact 
that clones examined were resistant to dexamethasone may be due to the 
cloning process that selected for those clones showing vigorous growth. By 
choosing these clones we may have a more resistant type of cell. It is of note 
that two clones had a significant increase in proliferation in response to 
exogenous IL-15. These results require further investigation, hivestigators 
have already demonstrated the presence of IL-15 mRNA and protein in the 
microenvironment of plasma cells (Mrozek et al, 1996) which may suggest 
the possibility of paracrine stimulation.
hi order to further investigate the effects of exogenous IL-6 and IL-15, cell 
cycle experiments were carried out. Cell cycle and apoptosis assays were
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perforaied on the U266 clones with IL-6 or IL-15 alone or in combination 
with dexamethasone. These cell cycle studies confirm the proliferation 
results on U266. The dexamethasone sensitivity did not result in cell death 
by apoptosis, but rather G1 arrest which were reversed significantly with the 
addition of IL-6. Although dexamethasone is considered to be apoptotic, no 
such apoptotic effect was observed. It has been reported that IL-15 may 
protect the cells from apoptosis (Hjorth-Hansen et al 1999) but this has not 
been demonstrated, as these cells are resistant to apoptosis.
Conclusions
We have demonstrated that myeloma clones producing TGF-j3 mRNA 
transcripts (produced significantly high levels of TGF-p protein) can 
suppress T cell proliferation. Suppression of IL-2 T cell responses may be 
mediated by TGF-P since it prevents T cell proliferation by inhibiting the 
phosphorylation of Jak-1 kinase activation of STAT 5 transcription factor 
(Bright et al, 1997). This prevents T cells from entering the IL-2 autocrine 
growth pathway. The combination of IL-15 and TGF-p enliances 
suppression of T cell proliferation. The myeloma clones expressed mRNA 
transcripts for IL-6, IL-15, IL-15R and TGF-p. Due to these findings the 
effects of exogenous IL-6, IL-15 and dexamethasone on proliferation, cell 
cycle and apoptosis of the myeloma clones were investigated.
IL-6 and IL-15 did protect the U266 cells from the effects of dexamethasone 
at 50|ag/ml but not at lOOqg/ml. IL-6 did not induce any significant
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proliferation. In contrast, IL-15 induced proliferation of the clone M l 
(expresses IL-6, TGF-p mRNA transcripts) and M l6 (expresses TGF-p 
mRNA transcripts). However, M l6 did not always proliferate in the 
presence of IL-15, other soluble factors may be involved. Interestingly 
exogenous IL-15 in combination with dexamethasone significantly 
decreases proliferation in the clone M3 (expresses IL-15, TGF-p mRNA 
transcripts) that is resistant to the effects of dexamethasone. The role of 
IL-15 is complex and seems to be dependent on what other cytokines 
/factors are present.
Further studies in the interrelationship of IL-6 / IL-15 / TGF-/3 are needed in 
both cell lines and fresh MM cells obtained from patients.
The use of immunotherapy in MM is becoming more attractive as the value 
of donor lymphocyte infusions (DLI) after allogeneic BMT, and the 
beneficial effect of the immuno-modulating agent thalidomide, is becoming 
more apparent. TGF-P induced immunosuppression can be overcome by 
stimulating pre-transplant T cells with IL-15, after which the T cells are 
again responsive to IL-2. However, before the use of agents such as IL-15 
can be considered for in vivo use, it is essential to clarify the possible direct 
effect this and other agents may have on the MM cells.
MM is a clonal expansion of malignant plasma cells in the bone maiTOW. 
Complex interactions between the malignant cells and the cells of the 
microenvironment (e.g. osteoblasts, osteoclasts and stromal cells) control 
the growth of these MM cells. Although EL-6 is a major growth factor in this 
microenviromnent, several local gi’owth factors are deposited in bone by
oseoblasts, these factors are released as the bone is reabsorbed. Bone 
mari'ow stromal cells and myeloma cells produce TGF-P. This factor is also 
deposited in bone and released when it is reabsorbed. IL-6 production is 
stimulated by TGF-p. Therefore the bone derived TGF-P may also 
contribute to the production of IL-6. Another local factor, hisulin like 
growth factor-1 (IGF-l), is deposited in bone; IGF-1 supports the growth of 
myeloma cells (Jelinek et al, 1997). hi addition dexamethasone induced 
apoptosis is prevented by IGF-1 (Xu et al, 1997).
It has been suggested that reabsorbing bone and the cells involved in that 
process may be important in generating the appropriate environment for the 
proliferation and smwival of malignant plasma cells, hiiproving our 
understanding of these interactions may provide us with opportunities to 
identify new therapeutic approaches to treating MM.
Thus, although the data presented in this study provide valuable preliminary 
information; frirther studies are required.
Ideally, these should include experiments in which the role of the bone 
marrow microenvironment is investigated.
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